PubMed HealthSearch

Biomedical subjects

J Vacl

Publications and source records attributed to J Vacl.

At least 19 recordsLinked to original sources

Protein cross-match test for the diagnosis and prevention of reactions after the transfusion of blood and cryoprecipitate.

The examination by means of counterimmunoelectrophoresis for protein incompatibility of the serum of 62 patients who developed an allergic or pyretic post-transfusion reaction revealed incompatibility in 23 cases (37.2%). It was due to the presence of antibodies in 8 recipients (34.8%) and in 15 blood donors (65.2%). The incidence was significantly higher than in a control group of transfused patients who did not develop a reaction. In this group protein incompatibility was found in only 14.7%, 80% of which was due to antibodies in the recipient. In 13 (56.5%) of the patients with reactions agglutinating, cytotoxic or complement fixing antibodies against cellular antigens or IgG were found in addition to protein incompatibility. In 10 cases (43.5%) protein incompatibility was the only explanation for the clinical symptoms. When, in the treatment of multiply transfused haemophiliacs who regularly developed adverse reactions, donors for the preparation of cryoprecipitate were selected by means of the described technique, the almost obligatory reactions were prevented.

Antibodies

[Determination of the C3 component in relation to paternity suits].

The C3 component which is a part of the complement appears to be of significance in assessing fatherhood in paternity causes. Its occurrence follow hereditary laws, in homozygotes the phenotype is represented by one, in heterozypotes by two zones designated as S, F and SF. The demonstration depends on the quality of the serum and the laboratory technique used. The same applies to the reliability of the readings.

Complement C3

Anti-HBbrno: a new CIEP hepatitis B marker, more sensitive than HBsAg radioimmunoassay.

Evidence is presented for the new HBbrnoAg-Anti-HGbrno system association with the HBsAg. The association is displayed particularly in a prevalence of Ausria detectable HBsAg carriers among the anti-HBbrno carriers, suggesting the anti-HBbrno to be a marker of contact with hepatitis B or, possibly, an indicator of co-existing HBsAg antigenaemia, not detectable by radioimmunoassay. Identity of HBbrnoAg with HBsAg/a, d, y, w, is ruled out, the identity with the other HBV associated antigenic specificities remaining questionable.

Antigen-Antibody Complex

Quantitation of the ABO system antigens by means of isoprecipitating antisera.

A quantitative method for the determination of blood group specific substances A and B on red blood cells was developed, using them to absorb isoprecipitating antisera anti-A and anti-B, followed by estimation of the residual antibody by means of a counterimmunoelectrophoretic technique with standard solutions of A and B substances prepared from saliva. The method was tested on a population of A2B donors. The mean amount of A substance in A2B RBC was 131 X 10(-12) +/- 217 X 10(-12) u/cell in the population of 95 donors. The A substance thus determined agreed significantly with values obtained by classical haemagglutinating titration. The mean amount of B substance in A2B RBC was 222 X 10(-12) +/- 178 X 10(-12) m/cell. The amounts of both the A and B substances were not correlated on the same RBC. Several peaks of the distribution curve of both substances confirmed the non-homogeneity of the populations, there being a wide standard deviation presumably due to differences in the antigen content of different subgroups.

ABO Blood-Group System